Zai Lab Reports Positive First-in-Human Data for ZL-1503 in Atopic Dermatitis

The signal here is mechanistic rather than financial: a bispecific hitting both IL-13 and IL-31 receptor alpha targets two distinct drivers of atopic dermatitis itch and inflammation, and the long-acting profile is the commercial thesis. But this is single-ascending-dose, preliminary data from a first-in-human study — early tolerability and pharmacokinetics, not efficacy. The competitive read-across is to the established IL-13 and IL-31 players this candidate would eventually sit alongside. The open question is whether the dose-sparing claim holds through the multiple-ascending-dose portion and whether the ACAAI 2026 presentation adds durability data beyond the headline.